IP Library › Granted Patent US 12,521,403
Granted Patent B2
US 12,521,403 · App. 17/592,426 · Granted Jan 13, 2026

Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith

Inventors: Thierry Vancaillie (Castlecrag, AU); Alan Hewitt (Wrexham, AU)
Assignee: TA Pharma Pty Limited
A61K31/565A61K9/0014A61K9/06A61K9/107A61K31/135A61K31/55A61K31/566A61K31/567A61K45/06A61K47/14A61K47/183A61K47/24A61K47/32A61K47/34A61K47/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,521,403
App. No.
17/592,426
Granted
Jan 13, 2026
Kind
B2
Abstract

Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

Claims (3)

1 . A composition, comprising a pluronic lecithin organogel comprising estriol and a tricyclic antidepressant selected from amitriptyline and nortriptyline, wherein the composition is formulated for topical, transdermal or transmucosal administration.

2 . A composition according to claim 1 , wherein the composition is a topical composition.

3 . A composition according to claim 1 , wherein the organogel comprises estriol and amitriptyline.

Assignments (2)
CHANGE OF NAME Recorded Nov 5, 2025
From: T & A PHARMA PTY LTD
To: TA PHARMA PTY LTD
Reel/Frame 073215/0945 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: VANCAILLIE, THIERRY; HEWITT, ALAN
To: T & A PHARMA PTY LIMITED
Reel/Frame 059225/0765 →
Priority Claims (1)
AU 2016901605 · May 2, 2016 · national
Continuity (2)
Continuation 16098428
Related Publication 20220152047A1 · May 19, 2022
References Cited (29)
US 5837289A · Grasela · 1998 [cited by applicant]
US 5976547A · Archer · 1999 [cited by examiner]
US 11273164B2 · Vancaillie et al. · 2022 [cited by applicant]
US 20020099003A1 · Wilson · 2002 [cited by applicant]
US 20040044080A1 · Place · 2004 [cited by applicant]
US 20040198706A1 · Carrara · 2004 [cited by applicant]
US 20070292461A1 · Tamarkin et al. · 2007 [cited by applicant]
US 20160051683A1 · Banov · 2016 [cited by applicant]
WO WO9745125 · 1997 [cited by applicant]
WO WO2007021805 · 2007 [cited by applicant]
WO WO2010118461 · 2010 [cited by applicant]
WO WO2014018563 · 2014 [cited by applicant]
Belgamwar et al., “Pluronic lecithin organogel,” Asian J. of Pharmaceutics (2008) pp. 134-138. [cited by applicant]
Boardman, “Topical Therapy for Vulvodynia,” NVA News (2005) vol. XI, Issue 1, 12 pages. [cited by applicant]
Cox et al., “Assessment and management options for women with vulvodynia”, Journal of Midwifery & Women's Health (2012) 57(3):231-240. [cited by applicant]
Database Medline, accession No. NLM21846439 (2011) 2 pages. [cited by applicant]
Gardella et al., Effect of local estrogen therapy (LET) on urinary and sexual symptoms in premenopausal eomen with interstitial cystitis/bladder pain syndrome (IC/BPS) Gynecological Endocrinology (2015) 31(10): English … [cited by applicant]
Haefner et al., “The Vulvodynia Guideline,” Journal of Lower Genital Tract Disease (2005) 9(1):40-51. [cited by applicant]
Head, “Estriol: Safety and Efficacy,” Alternative Medicine Review (1998) 3(2):101-113. [cited by applicant]
Lotery et al., “Vulvodynia,” The Lancet (2004) 363:1058-1060. [cited by applicant]
Loyd et al., “The History of Pluronic Lecithin Organogel: an Interview With Marty Jones, Bspharm, FACA, FIACP,” International Journal of Pharmacceutical Compounding (2003) 7(3):180-183. [cited by applicant]
Methodist Physicians Clinic, “Vulvodynia”, [retrieved from internet on Jun. 27, 2017] <URL: http://www.methodistsexualwellness.com/services/vulvodynia/> published on Mar. 26, 2016. [cited by applicant]
Pagano et al., “Use of Amitriptyline Cream in the Management of Entry Dyspareunia Due to Provoked Vestibulodynia,” Journal of Lower Genital Tract Disease (2012) 16(4):394-397. [cited by applicant]
Pandey et al., “Pluronic lecithin organogel as a topical drug delivery system,” Drug Delivery (2010) 17(1):38-47. [cited by applicant]
Perez-Lopez and Hita-Contreras, “Management of pudendal neuralgia,” Climacteric (2014) 17:654-656. [cited by applicant]
Ruoss et al., “Topical treatment of vulvodynia, dyspareunia and pudendal neuralgia: A single clinic audit of amitriptyline and oestriol in organogel,” Aust N Z J Obstet Gynaecol (2021) 1-5. [cited by applicant]
Sahoo et al., “Organogels: Properties and Applications in Drug Delivery,” Designed Monomers and Polymers (2011) 14:95-108. [cited by applicant]
Shah et al., “Update in Diagnosis and Treatment of Chronic Pelvic Pain Syndromes,” Curr. Bladder Dysfunct. Rep. (2015) 10(3):198-206. [cited by applicant]
Loyd, “The history of pluronic lecithin organogel,” International Journal Pharmaceutical Compounding (2003) 7(3): 180-183. [cited by applicant]